Drug sensitivity analysis revealed that cancer patients with low‐expression levels of the NLRP1 gene demonstrated heightened sensitivity to SNX‐2112, Dabrafenib, Momelotinib, Dacarbazine, AZD7762, NSC632839, and Merck60 (r value < −0.2, FDR < 0.001) based on the findings from the CTRP dataset (Figure 6A). Here, NLRP1 is linked to cancer.